1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD20
  4. CD20 Inhibitor

CD20 Inhibitor

CD20 Inhibitors (30):

Cat. No. Product Name Effect Purity
  • HY-P99033
    Mosunetuzumab
    Inhibitor 99.05%
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
  • HY-185428
    TRS-005
    Inhibitor
    TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma).
  • HY-P992104
    Blidarvetug
    Inhibitor
    Blidarvetug is a veterinary monoclonal antibody targeting MS4A1/CD20, which can be used to study CD20-positive B-cell lymphoma in dogs.
  • HY-P9952
    Belimumab
    Inhibitor 99.40%
    Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
  • HY-P990806
    Anti-Mouse CD20 Antibody (MB20-11)
    Inhibitor 98.79%
    Anti-Mouse CD20 Antibody (MB20-11) is a kind of mouse IgG2c antibody inhibitor, targeting to CD20. Anti-Mouse CD20 Antibody (MB20-11) can deplete mature B cells in lymphoid tissues. Anti-Mouse CD20 Antibody (MB20-11) can be used for the researches of cancer, immunology and metabolic Disease, such as lymphoma and diabetes.
  • HY-P9960
    Ocrelizumab
    Inhibitor ≥99.0%
    Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).
  • HY-P990139
    Anti-Mouse CD20 Antibody (AISB12)
    Inhibitor
    Anti-Mouse CD20 Antibody (AISB12) is an anti-mouse CD20 IgG2a monoclonal antibody. Anti-Mouse CD20 Antibody (AISB12) can deplete B cells. Anti-Mouse CD20 Antibody (AISB12) can be used for research on immunology.
  • HY-P99538
    Ublituximab
    Inhibitor 98.42%
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects.
  • HY-P99326
    Tositumomab
    Inhibitor
    Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma.
  • HY-P99483
    Blontuvetmab
    Inhibitor 99.08%
    Blontuvetmab (AT 004) is a canine-derived CD20 monoclonal antibody, and it is used for research on canine B-cell lymphoma.
  • HY-P99776
    Plamotamab
    Inhibitor 99.12%
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
  • HY-P99308
    Ocaratuzumab
    Inhibitor
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
  • HY-P99952
    Ripertamab
    Inhibitor
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).
  • HY-P99855
    Divozilimab
    Inhibitor 99.63%
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
  • HY-P990649
    PF-5212374
    Inhibitor
    PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases.
  • HY-P991671
    Anafiltamig
    Inhibitor
    Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
  • HY-P99660
    Imvotamab
    Inhibitor
    Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
  • HY-P991548
    BLX-301
    Inhibitor
    BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis.
  • HY-P992349
    DXL625
    Inhibitor
    DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.
  • HY-P991514A
    MIL62 (FUT8-KO)
    Inhibitor
    MIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody.